1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Biocartis Group NV
  6. Summary
    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-08-05 am EDT
1.718 EUR   +2.14%
06/22ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively
DJ
06/22Biocartis, AstraZeneca To Jointly Develop Companion Lung Cancer Diagnostic Test For Tagrisso
MT
06/22PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
08/01/2022 08/02/2022 08/03/2022 08/04/2022 08/05/2022 Date
1.72(c) 1.7(c) 1.7(c) 1.682(c) 1.718(c) Last
22 662 82 246 48 597 46 195 72 591 Volume
0.00% -1.16% 0.00% -1.06% +2.14% Change
More quotes
Estimated financial data (e)
Sales 2022 63,8 M 64,7 M 64,7 M
Net income 2022 -53,0 M -53,8 M -53,8 M
Net Debt 2022 151 M 153 M 153 M
P/E ratio 2022 -1,83x
Yield 2022 -
Sales 2023 88,3 M 89,6 M 89,6 M
Net income 2023 -37,0 M -37,6 M -37,6 M
Net Debt 2023 178 M 181 M 181 M
P/E ratio 2023 -2,64x
Yield 2023 -
Capitalization 98,9 M 100 M 100 M
EV / Sales 2022 3,92x
EV / Sales 2023 3,14x
Nbr of Employees 619
Free-Float 86,6%
More Financials
Company
Biocartis Group NV specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes. Net sales by source of income... 
More about the company
Ratings of Biocartis Group NV
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about BIOCARTIS GROUP NV
06/22ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively
DJ
06/22Biocartis, AstraZeneca To Jointly Develop Companion Lung Cancer Diagnostic Test For Tag..
MT
06/22PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces New Agreement with AstraZeneca for ..
GL
06/22PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces New Agreement with AstraZeneca for ..
AQ
06/22Biocartis Group NV Announces New Agreement with Astrazeneca for the Development and Mar..
CI
06/20Molecular Diagnostics Group Biocartis Introduces Lung Cancer Testing Panel
MT
06/20PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Launch of its Rapid CE-marked IVD I..
GL
06/20Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel ..
CI
06/20PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Launch of its Rapid CE-marked IVD I..
GL
06/15PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Reaches Key Commercial Milestones: One-Millio..
GL
06/15PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Reaches Key Commercial Milestones: One-Millio..
AQ
05/13PRESS RELEASE BIOCARTIS GROUP NV : Results of the Annual Shareholders' Meeting held on 13 ..
GL
05/13BIOCARTIS GROUP NV : Proxy Statments
CO
05/04PRESS RELEASE BIOCARTIS GROUP NV : New Study Led by Memorial Sloan Kettering Cancer Center..
GL
05/04PRESS RELEASE BIOCARTIS GROUP NV : New Study Led by Memorial Sloan Kettering Cancer Center..
GL
More news
News in other languages on BIOCARTIS GROUP NV
07/27Melexis uitblinker op groene Brusselse beurs
06/24Bel20 in het groen
06/22ASTRAZENECA : l'EMA accepte un dossier dans le cancer du sein
06/22Rode start in Brussel verwacht
06/22Biocartis et AstraZeneca vont développer conjointement un test compagnon de diagnostic ..
More news
Chart BIOCARTIS GROUP NV
Duration : Period :
Biocartis Group NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCARTIS GROUP NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,72 €
Average target price 4,75 €
Spread / Average Target 176%
EPS Revisions
Managers and Directors
Herman Verrelst Chief Executive Officer
Jean-Marc Roelandt Chief Financial Officer
Christian Reinaudo Independent Chairman
Benoit Devogelaere Chief Technology Officer
Piet Houwen Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOCARTIS GROUP NV-52.48%100
MASIMO CORPORATION-47.59%8 518
SHOCKWAVE MEDICAL, INC.25.13%7 987
NOVOCURE LIMITED0.72%7 920
PENUMBRA, INC.-41.94%6 321
GETINGE AB-44.19%5 869